Stay updated on MK-2870-004 Clinical Trial
Sign up to get notified when there's something new on the MK-2870-004 Clinical Trial page.

Latest updates to the MK-2870-004 Clinical Trial page
- Check3 days agoChange DetectedThe page revision label was updated from v3.6.3 to v3.6.4, indicating an incremental release of the site. No visible content changes for the study details are described in the provided changes.SummaryDifference0.0%

- Check10 days agoChange DetectedJuly 2026 update dates were added to the study record and June 2026 dates were removed, updating the record's modification history to reflect recent changes.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe page revision updated from v3.6.2 to v3.6.3, indicating a new version of the study record. This likely reflects minor edits or corrections to the page.SummaryDifference0.0%

- Check32 days agoChange DetectedRevision: v3.6.2 is now shown on the page, indicating an updated version of the page. This reflects a minor revision to the page rather than a substantive content change.SummaryDifference0.0%

- Check39 days agoChange DetectedAdds a detailed study purpose describing the comparison between sacituzumab tirumotecan and chemotherapy for NSCLC with EGFR mutations or other genomic alterations, and introduces explicit primary and secondary endpoints (OS and PFS) with definitions and time frames; older language about multiple primary hypotheses has been removed.SummaryDifference0.3%

- Check46 days agoChange DetectedNew help and navigation sections were added to assist visitors in understanding the study record, including How to Read a Study Record, Common Questions, and How to Join a Study, plus a note that enrollment is 'No longer looking for participants'. The Intervention/Treatment header formatting was standardized, and the page revision badge shows v3.6.0.SummaryDifference0.1%

Stay in the know with updates to MK-2870-004 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MK-2870-004 Clinical Trial page.